Dynavax Technologies Co. (NASDAQ:DVAX) – Equities researchers at Cantor Fitzgerald reduced their FY2018 EPS estimates for Dynavax Technologies in a research note issued on Sunday. Cantor Fitzgerald analyst E. Piros now anticipates that the biopharmaceutical company will earn ($1.72) per share for the year, down from their previous forecast of ($1.65). Cantor Fitzgerald currently has a “Overweight” rating and a $27.00 target price on the stock.
Several other equities analysts have also commented on DVAX. Royal Bank of Canada restated a “buy” rating and set a $25.00 price target on shares of Dynavax Technologies in a research note on Friday, March 9th. BidaskClub lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Cowen reaffirmed a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research report on Wednesday, February 21st. Zacks Investment Research downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Finally, ValuEngine downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Dynavax Technologies has a consensus rating of “Hold” and an average price target of $24.67.
Shares of Dynavax Technologies (NASDAQ:DVAX) traded down $0.03 during trading on Wednesday, hitting $16.42. The stock had a trading volume of 607,197 shares, compared to its average volume of 1,407,719. The stock has a market capitalization of $999.23, a price-to-earnings ratio of -8.88 and a beta of 1.05. Dynavax Technologies has a 1 year low of $5.00 and a 1 year high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.32). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.53 million. Dynavax Technologies had a negative net margin of 29,099.08% and a negative return on equity of 57.43%.
In related news, insider David F. Novack sold 2,121 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $17.97, for a total transaction of $38,114.37. Following the sale, the insider now owns 77,192 shares of the company’s stock, valued at $1,387,140.24. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP David Louis Johnson sold 3,092 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $18.60, for a total value of $57,511.20. Following the sale, the vice president now directly owns 7,780 shares in the company, valued at approximately $144,708. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,427 shares of company stock worth $660,841. 2.90% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of DVAX. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Dynavax Technologies by 474.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 5,880 shares in the last quarter. Royal Bank of Canada boosted its holdings in Dynavax Technologies by 17.0% in the second quarter. Royal Bank of Canada now owns 20,454 shares of the biopharmaceutical company’s stock worth $198,000 after acquiring an additional 2,975 shares in the last quarter. Voya Investment Management LLC boosted its holdings in Dynavax Technologies by 26.3% in the second quarter. Voya Investment Management LLC now owns 21,403 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 4,462 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in Dynavax Technologies in the fourth quarter worth about $257,000. Finally, SG Americas Securities LLC acquired a new stake in Dynavax Technologies in the third quarter worth about $287,000. 72.52% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “FY2018 EPS Estimates for Dynavax Technologies Co. (DVAX) Lowered by Cantor Fitzgerald” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://ledgergazette.com/2018/03/16/fy2018-eps-estimates-for-dynavax-technologies-co-dvax-lowered-by-cantor-fitzgerald.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.